<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2016-05-24" updated="2020-01-02">
  <drugbank-id primary="true">DB11601</drugbank-id>
  <name>Tuberculin Purified Protein Derivative</name>
  <description>Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines.</description>
  <cas-number/>
  <unii>I7L8FKN87J</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A19533</ref-id>
        <pubmed-id>22762692</pubmed-id>
        <citation>Yang H, Kruh-Garcia NA, Dobos KM: Purified protein derivatives of tuberculin--past, present, and future. FEMS Immunol Med Microbiol. 2012 Dec;66(3):273-80. doi: 10.1111/j.1574-695X.2012.01002.x. Epub 2012 Aug 1.</citation>
      </article>
      <article>
        <ref-id>A19534</ref-id>
        <pubmed-id>23870090</pubmed-id>
        <citation>Prasad TS, Verma R, Kumar S, Nirujogi RS, Sathe GJ, Madugundu AK, Sharma J, Puttamallesh VN, Ganjiwale A, Myneedu VP, Chatterjee A, Pandey A, Harsha H, Narayana J: Proteomic analysis of purified protein derivative of Mycobacterium tuberculosis. Clin Proteomics. 2013 Jul 19;10(1):8. doi: 10.1186/1559-0275-10-8.</citation>
      </article>
      <article>
        <ref-id>A19537</ref-id>
        <pubmed-id>11972637</pubmed-id>
        <citation>Matsuyama W, Kubota R, Hashiguchi T, Momi H, Kawabata M, Nakagawa M, Arimura K, Osame M: Purified protein derivative of tuberculin upregulates the expression of vascular endothelial growth factor in T lymphocytes in vitro. Immunology. 2002 May;106(1):96-101.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T28</ref-id>
        <isbn>978-0-7020-3471-8</isbn>
        <citation>6. (2012). In Rang and Dale's Pharmacology  (7th ed., pp. 82-84). Edinburgh: Elsevier/Churchill Livingstone.</citation>
      </textbook>
    </textbooks>
    <links>
      <link>
        <ref-id>L806</ref-id>
        <title>Tubersol (Tuberculin Purified Protein Derivative) product information</title>
        <url>https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm114924.pdf</url>
      </link>
      <link>
        <ref-id>L778</ref-id>
        <title>World Health Organization Model List of Essential Medicines (19th List)</title>
        <url>http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated as a diagnostic agent in Mantoux Test used to detect infection with *Mycobacterium tuberculosis*. </indication>
  <pharmacodynamics>It is intradermally administered to facilitate detection of active tuberculosis caused by *Mycobacterium tuberculosis*. Tuberculin PPD is an inactivated purified protein fraction obtained from human strain of *Mycobacterium tuberculosis*and antigen that induces a delayed hypersensitivity response after few hours following administration. When the person has already acquired the tuberculin antigen, the immune response is stimulated to produce antigen-specific T cells that circulate in the bloodstream for up to several months and years. Clinically, a delayed hypersensitivity reaction to tuberculin is a manifestation of previous infection with M tuberculosis or a variety of non-tuberculosis bacteria. In most cases sensitization is induced by natural mycobacterial infection or by vaccination with BCG Vaccine. The antigen causes, pain, edema and infiltration of immune cells in the injection area. </pharmacodynamics>
  <mechanism-of-action>When exposed to *M. tuberculosis* antigen, the sensitization initiates in the regional lymph nodes where T lymphocytes proliferate in response to the antigenic stimulus to give rise to specifically sensitized lymphocytes which may exist in the circulation up to many years. Antigen is presented to T cells by being ingested by antigen presenting cells (APC), which then present it on their surface to lymphocytes in combination with various MHC molecules once they reach local lymph nodes [T28]. Tuberculin PPD most likely interacts with toll-like receptor 2 expressed on APCs that initiates an inflammatory response. Subsequent restimulation of these sensitized lymphocytes with the same or a similar antigen, such as the intradermal injection of tuberculin PPD, evokes a local reaction mediated by these cells. This reaction is referred to as a delayed-type hypersensitivity response that includes vasodilation, edema, and the infiltration of lymphocytes, basophils, monocytes, and neutrophils into the site of antigen injection. The sensitized antigen-specific T lymphocytes proliferate and release lymphokines, which mediate the accumulation of other cells at the site [L806]. In vitro studies show that Tuberculin PPD promotes the upregulation of vascular endothelial growth factor (VEGF) expression in T lymphocytes through major histocompatibility (MHC) class II interaction with CD4+ T lymphocyte interaction [A19537]. The reactions are evident after 5-6 hours following administration. </mechanism-of-action>
  <toxicity>Some adverse effects at the injection site include pain, discomfort, pyrexia, and erythema, rash, hemorrhage, hematoma and rarely ulcer and necrosis. Other unwanted effects include severe hypersensitivity reactions, dyspnea, generalized rash and syncope. </toxicity>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Mycobacterium tuberculosis purified protein derivative</synonym>
    <synonym language="english" coder="">Purified protein derivative of tuberculin</synonym>
    <synonym language="english" coder="">Tuberculin PPD</synonym>
    <synonym language="english" coder="">Tuberculin, purified protein derivative</synonym>
    <synonym language="english" coder="">Tuberculin,purified protein derivative</synonym>
    <synonym language="spanish" coder="">Tuberculina PPD</synonym>
    <synonym language="english" coder="">Tuberculinum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Aplisol</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-0104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>5 [iU]/0.1mL</strength>
      <route>Intradermal</route>
      <fda-application-number>BLA103782</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aplisol</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1336</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>5 [iU]/0.1mL</strength>
      <route>Intradermal</route>
      <fda-application-number>BLA103782</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aplisol</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-786</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>5 [iU]/0.1mL</strength>
      <route>Intradermal</route>
      <fda-application-number>BLA103782</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aplisol</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>42023-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>5 [iU]/0.1mL</strength>
      <route>Intradermal</route>
      <fda-application-number>BLA103782</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tuberculin Ppd (mantoux)</name>
      <labeller>Aventis Pasteur Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00317233</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-12-31</started-marketing-on>
      <ended-marketing-on>2001-07-19</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intradermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tuberculin Ppd (mantoux)</name>
      <labeller>Aventis Pasteur Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00316377</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-12-31</started-marketing-on>
      <ended-marketing-on>2001-07-19</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intradermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tubersol</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0261</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1956-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 [iU]/0.1mL</strength>
      <route>Intradermal</route>
      <fda-application-number>BLA103941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tubersol</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3356</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1956-08-15</started-marketing-on>
      <ended-marketing-on>2013-06-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 [iU]/0.1mL</strength>
      <route>Intradermal</route>
      <fda-application-number>BLA103941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tubersol</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2972</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1956-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 [iU]/0.1mL</strength>
      <route>Intradermal</route>
      <fda-application-number>BLA103941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tubersol</name>
      <labeller>Sanofi Pasteur Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00317268</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5 tub</strength>
      <route>Intradermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tubersol</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1668</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1956-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 [iU]/0.1mL</strength>
      <route>Intradermal</route>
      <fda-application-number>BLA103941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tubersol</name>
      <labeller>Sanofi Pasteur Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49281-752</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1956-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 [iU]/0.1mL</strength>
      <route>Intradermal</route>
      <fda-application-number>BLA103941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Tubersol</name>
      <ingredients>Tuberculin Purified Protein Derivative</ingredients>
    </mixture>
    <mixture>
      <name>Tubersol</name>
      <ingredients>Tuberculin Purified Protein Derivative</ingredients>
    </mixture>
    <mixture>
      <name>Aplisol</name>
      <ingredients>Tuberculin Purified Protein Derivative</ingredients>
    </mixture>
    <mixture>
      <name>Aplisol</name>
      <ingredients>Tuberculin Purified Protein Derivative</ingredients>
    </mixture>
    <mixture>
      <name>Tubersol</name>
      <ingredients>Tuberculin Purified Protein Derivative</ingredients>
    </mixture>
    <mixture>
      <name>Aplisol</name>
      <ingredients>Tuberculin Purified Protein Derivative</ingredients>
    </mixture>
    <mixture>
      <name>Aplisol</name>
      <ingredients>Tuberculin Purified Protein Derivative</ingredients>
    </mixture>
    <mixture>
      <name>Tubersol</name>
      <ingredients>Tuberculin Purified Protein Derivative</ingredients>
    </mixture>
    <mixture>
      <name>Tubersol</name>
      <ingredients>Tuberculin Purified Protein Derivative</ingredients>
    </mixture>
    <mixture>
      <name>Tubersol</name>
      <ingredients>Tuberculin Purified Protein Derivative</ingredients>
    </mixture>
    <mixture>
      <name>Tuberculin Ppd (mantoux)</name>
      <ingredients>Tuberculin Purified Protein Derivative</ingredients>
    </mixture>
    <mixture>
      <name>Tuberculin Ppd (mantoux)</name>
      <ingredients>Tuberculin Purified Protein Derivative</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Antigens</category>
      <mesh-id>D000941</mesh-id>
    </category>
    <category>
      <category>Antigens, Bacterial</category>
      <mesh-id>D000942</mesh-id>
    </category>
    <category>
      <category>Antihistamine Drugs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Cell-mediated Immunity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Indicators and Reagents</category>
      <mesh-id>D007202</mesh-id>
    </category>
    <category>
      <category>Laboratory Chemicals</category>
      <mesh-id>D019995</mesh-id>
    </category>
    <category>
      <category>Skin Test Antigen</category>
      <mesh-id/>
    </category>
    <category>
      <category>Tuberculin</category>
      <mesh-id>D014373</mesh-id>
    </category>
    <category>
      <category>Tuberculosis</category>
      <mesh-id>D014376</mesh-id>
    </category>
    <category>
      <category>Tuberculosis Skin Test</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Injection</form>
      <route>Intradermal</route>
      <strength>5 [iU]/0.1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intradermal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intradermal</route>
      <strength>5 [iU]/0.1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intradermal</route>
      <strength>5 tub</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>04:00.00</ahfs-code>
    <ahfs-code>36:84.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB11601.pdf?1464130365</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB11601.pdf?1496853751</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7783</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347911212</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0001164</id>
      <name>Toll-like receptor 2</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19539</ref-id>
            <pubmed-id>27942355</pubmed-id>
            <citation>Biyikli OO, Baysak A, Ece G, Oz AT, Ozhan MH, Berdeli A: Role of Toll-Like Receptors in Tuberculosis Infection. Jundishapur J Microbiol. 2016 Sep 14;9(10):e20224. eCollection 2016 Oct.</citation>
          </article>
          <article>
            <ref-id>A19540</ref-id>
            <pubmed-id>19056540</pubmed-id>
            <citation>Strapagiel D, Kasztalska K, Druszczynska M, Kowalewicz-Kulbat M, Vrba A, Matusiak A, Chmiela M, Rudnicka W: Monocyte response receptors in BCG driven delayed type hypersensitivity to tuberculin. Folia Histochem Cytobiol. 2008;46(3):353-9. doi: 10.2478/v10042-008-0044-1.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="O60603" source="Swiss-Prot">
        <name>Toll-like receptor 2</name>
        <general-function>Triacyl lipopeptide binding</general-function>
        <specific-function>Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components. Cooperates with TLR1 or TLR6 to mediate the innate immune response to bacterial lipoproteins or lipopeptides (PubMed:17889651). Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also promote apoptosis in response to lipoproteins (PubMed:10426996). Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6 (PubMed:11441107). Acts as a receptor for M.tuberculosis lipoproteins LprA, LprG, LpqH and PhoS1 (pstS1), some lipoproteins are dependent on other coreceptors (TLR1, CD14 and/or CD36).The lipoproteins act as agonists to modulate antigen presenting cell functions in response to the pathogen (PubMed:19362712). Forms activation clusters composed of several receptors depending on the ligand, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway. Forms the cluster TLR2:TLR6:CD14:CD36 in response to diacylated lipopeptides and TLR2:TLR1:CD14 in response to triacylated lipopeptides (PubMed:16880211).</specific-function>
        <gene-name>TLR2</gene-name>
        <locus>4q32</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>589-609</transmembrane-regions>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>6.59</theoretical-pi>
        <molecular-weight>89836.575</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11848</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>TLR2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF051152</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3132528</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O60603</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TLR2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>TIL4</synonym>
          <synonym>Toll/interleukin-1 receptor-like protein 4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010812|Toll-like receptor 2
MPHTLWMVWVLGVIISLSKEESSNQASLSCDRNGICKGSSGSLNSIPSGLTEAVKSLDLS
NNRITYISNSDLQRCVNLQALVLTSNGINTIEEDSFSSLGSLEHLDLSYNYLSNLSSSWF
KPLSSLTFLNLLGNPYKTLGETSLFSHLTKLQILRVGNMDTFTKIQRKDFAGLTFLEELE
IDASDLQSYEPKSLKSIQNVSHLILHMKQHILLLEIFVDVTSSVECLELRDTDLDTFHFS
ELSTGETNSLIKKFTFRNVKITDESLFQVMKLLNQISGLLELEFDDCTLNGVGNFRASDN
DRVIDPGKVETLTIRRLHIPRFYLFYDLSTLYSLTERVKRITVENSKVFLVPCLLSQHLK
SLEYLDLSENLMVEEYLKNSACEDAWPSLQTLILRQNHLASLEKTGETLLTLKNLTNIDI
SKNSFHSMPETCQWPEKMKYLNLSSTRIHSVTGCIPKTLEILDVSNNNLNLFSLNLPQLK
ELYISRNKLMTLPDASLLPMLLVLKISRNAITTFSKEQLDSFHTLKTLEAGGNNFICSCE
FLSFTQEQQALAKVLIDWPANYLCDSPSHVRGQQVQDVRLSVSECHRTALVSGMCCALFL
LILLTGVLCHRFHGLWYMKMMWAWLQAKRKPRKAPSRNICYDAFVSYSERDAYWVENLMV
QELENFNPPFKLCLHKRDFIPGKWIIDNIIDSIEKSHKTVFVLSENFVKSEWCKYELDFS
HFRLFDENNDAAILILLEPIEKKAIPQRFCKLRKIMNTKTYLEWPMDEAQREGFWVNLRA
AIKS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010813|Toll-like receptor 2 (TLR2)
ATGCCACATACTTTGTGGATGGTGTGGGTCTTGGGGGTCATCATCAGCCTCTCCAAGGAA
GAATCCTCCAATCAGGCTTCTCTGTCTTGTGACCGCAATGGTATCTGCAAGGGCAGCTCA
GGATCTTTAAACTCCATTCCCTCAGGGCTCACAGAAGCTGTAAAAAGCCTTGACCTGTCC
AACAACAGGATCACCTACATTAGCAACAGTGACCTACAGAGGTGTGTGAACCTCCAGGCT
CTGGTGCTGACATCCAATGGAATTAACACAATAGAGGAAGATTCTTTTTCTTCCCTGGGC
AGTCTTGAACATTTAGACTTATCCTATAATTACTTATCTAATTTATCGTCTTCCTGGTTC
AAGCCCCTTTCTTCTTTAACATTCTTAAACTTACTGGGAAATCCTTACAAAACCCTAGGG
GAAACATCTCTTTTTTCTCATCTCACAAAATTGCAAATCCTGAGAGTGGGAAATATGGAC
ACCTTCACTAAGATTCAAAGAAAAGATTTTGCTGGACTTACCTTCCTTGAGGAACTTGAG
ATTGATGCTTCAGATCTACAGAGCTATGAGCCAAAAAGTTTGAAGTCAATTCAGAATGTA
AGTCATCTGATCCTTCATATGAAGCAGCATATTTTACTGCTGGAGATTTTTGTAGATGTT
ACAAGTTCCGTGGAATGTTTGGAACTGCGAGATACTGATTTGGACACTTTCCATTTTTCA
GAACTATCCACTGGTGAAACAAATTCATTGATTAAAAAGTTTACATTTAGAAATGTGAAA
ATCACCGATGAAAGTTTGTTTCAGGTTATGAAACTTTTGAATCAGATTTCTGGATTGTTA
GAATTAGAGTTTGATGACTGTACCCTTAATGGAGTTGGTAATTTTAGAGCATCTGATAAT
GACAGAGTTATAGATCCAGGTAAAGTGGAAACGTTAACAATCCGGAGGCTGCATATTCCA
AGGTTTTACTTATTTTATGATCTGAGCACTTTATATTCACTTACAGAAAGAGTTAAAAGA
ATCACAGTAGAAAACAGTAAAGTTTTTCTGGTTCCTTGTTTACTTTCACAACATTTAAAA
TCATTAGAATACTTGGATCTCAGTGAAAATTTGATGGTTGAAGAATACTTGAAAAATTCA
GCCTGTGAGGATGCCTGGCCCTCTCTACAAACTTTAATTTTAAGGCAAAATCATTTGGCA
TCATTGGAAAAAACCGGAGAGACTTTGCTCACTCTGAAAAACTTGACTAACATTGATATC
AGTAAGAATAGTTTTCATTCTATGCCTGAAACTTGTCAGTGGCCAGAAAAGATGAAATAT
TTGAACTTATCCAGCACACGAATACACAGTGTAACAGGCTGCATTCCCAAGACACTGGAA
ATTTTAGATGTTAGCAACAACAATCTCAATTTATTTTCTTTGAATTTGCCGCAACTCAAA
GAACTTTATATTTCCAGAAATAAGTTGATGACTCTACCAGATGCCTCCCTCTTACCCATG
TTACTAGTATTGAAAATCAGTAGGAATGCAATAACTACGTTTTCTAAGGAGCAACTTGAC
TCATTTCACACACTGAAGACTTTGGAAGCTGGTGGCAATAACTTCATTTGCTCCTGTGAA
TTCCTCTCCTTCACTCAGGAGCAGCAAGCACTGGCCAAAGTCTTGATTGATTGGCCAGCA
AATTACCTGTGTGACTCTCCATCCCATGTGCGTGGCCAGCAGGTTCAGGATGTCCGCCTC
TCGGTGTCGGAATGTCACAGGACAGCACTGGTGTCTGGCATGTGCTGTGCTCTGTTCCTG
CTGATCCTGCTCACGGGGGTCCTGTGCCACCGTTTCCATGGCCTGTGGTATATGAAAATG
ATGTGGGCCTGGCTCCAGGCCAAAAGGAAGCCCAGGAAAGCTCCCAGCAGGAACATCTGC
TATGATGCATTTGTTTCTTACAGTGAGCGGGATGCCTACTGGGTGGAGAACCTTATGGTC
CAGGAGCTGGAGAACTTCAATCCCCCCTTCAAGTTGTGTCTTCATAAGCGGGACTTCATT
CCTGGCAAGTGGATCATTGACAATATCATTGACTCCATTGAAAAGAGCCACAAAACTGTC
TTTGTGCTTTCTGAAAACTTTGTGAAGAGTGAGTGGTGCAAGTATGAACTGGACTTCTCC
CATTTCCGTCTTTTTGATGAGAACAATGATGCTGCCATTCTCATTCTTCTGGAGCCCATT
GAGAAAAAAGCCATTCCCCAGCGCTTCTGCAAGCTGCGGAAGATAATGAACACCAAGACC
TACCTGGAGTGGCCCATGGACGAGGCTCAGCGGGAAGGATTTTGGGTAAATCTGAGAGCT
GCGATAAAGTCCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01463</identifier>
            <name>LRRCT</name>
          </pfam>
          <pfam>
            <identifier>PF01582</identifier>
            <name>TIR</name>
          </pfam>
          <pfam>
            <identifier>PF13855</identifier>
            <name>LRR_8</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intrinsic component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane raft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Toll-like receptor 1-Toll-like receptor 2 protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Toll-like receptor 2-Toll-like receptor 6 protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>diacyl lipopeptide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lipopolysaccharide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lipopolysaccharide receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lipoteichoic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptidoglycan binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>signaling pattern recognition receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>Toll-like receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane signaling receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>triacyl lipopeptide binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface pattern recognition receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to bacterial lipopeptide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to diacyl bacterial lipopeptide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lipoteichoic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to peptidoglycan</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to triacyl bacterial lipopeptide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloramphenicol transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cytokine secretion involved in immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to Gram-positive bacterium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of diacyl bacterial lipopeptide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of triacyl bacterial lipopeptide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>I-kappaB phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>induction by symbiont of defense-related host nitric oxide production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>interleukin-10 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipopolysaccharide-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MyD88-dependent toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of growth of symbiont in host</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interleukin-12 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interleukin-17 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of chemokine production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytokine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-beta production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-12 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-18 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-6 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-8 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of macrophage cytokine production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric-oxide synthase biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tumor necrosis factor biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tumor necrosis factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of Wnt signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dendritic cell cytokine production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to molecule of fungal origin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 2 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 4 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor TLR1</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor TLR6</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>